Clinical efficacy of combining bifico with mesalazine in treatment of mild to moderate ulcerative colitis

Objective To evaluate the clinical efficacy of bifico combined with mesalazine in patients with mild to moderate ulcerative colitis(UC),and to explore its mechanism.Methods Sixty patients with mild to moderate active UC were randomized to combination group(n=30) and mesalazine group(n=30).The patients were treated by bifico and mesalazine in combination group and only by mesalazine in mesalazine group for 8 weeks.The changes of clinical symptoms and disease activity under endoscopy were evaluated before and after the treatment.The expression of NF-κB in colonic mucosa was also detected by immunohistochemical staining.Results The clinical symptoms and disease activity under endoscopy were improved more in combination group than in mesalazine group(P0.05).The expression of NF-κB significantly lower in combination group than that in mesalazine group(P0.05).Conclusion The combination of bifico and mesalazine is more effective than mesalazine alone in treatment of mild to moderate active UC.Bifico is an effective agent in the treatment of mild to moderate active UC probably by decreasing expression of NF-κB.